New and emerging agents in HER2-negative metastatic breast cancer: Implications for practice
2.7 هزار بار بازدید -
12 ماه پیش
-
emerging agents, including ADCs, for
emerging agents, including ADCs, for HER2-negative metastatic breast cancer and their impact on current and future practice.
With insights from Prof. Giuseppe Curigliano, Prof. Hope Rugo and Prof. Peter Schmid.
Watch now: https://touchoncologyime.org/new-and-...
--------
This activity is funded by an independent medical education grant from Gilead Sciences, Inc. and is jointly provided by USF Health and touchIME.
With insights from Prof. Giuseppe Curigliano, Prof. Hope Rugo and Prof. Peter Schmid.
Watch now: https://touchoncologyime.org/new-and-...
--------
This activity is funded by an independent medical education grant from Gilead Sciences, Inc. and is jointly provided by USF Health and touchIME.
12 ماه پیش
در تاریخ 1402/05/27 منتشر شده
است.
2,774
بـار بازدید شده